2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1364

Incidence of Rheumatoid Arthritis in a Cohort of First Degree Relatives from the Studies of the Etiology of Rheumatoid Arthritis
Abstract Number: 1365

Correlation of the Multi-Biomarker Disease Activity Score with Composite Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis
Abstract Number: 1366

Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients
Abstract Number: 1367

Circulating Microbial Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Abstract Number: 1368

Small RNA Sequencing Identifies Plasma microRNA Panel for Rheumatoid Arthritis Diagnosis
Abstract Number: 1369

Interferon Gamma Signature Genes and CXCL10 As New Biomarkers in Early Stage of Rheumatoid Arthritis
Abstract Number: 1370

Higher Disease Activity in Current Smokers with Established RA: Is It Disease, Damage or Disability?
Abstract Number: 1371

Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage
Abstract Number: 1372

A Single Immunosignature Test Accurately Discriminates RA from Related Autoimmune and Inflammatory Disorders
Abstract Number: 1373

Ultrasound of Subtalar Joint Synovitis in Patients with Rheumatoid Arthritis: Results of an Omeract Reliability Exercise Using Consensual Definitions
Abstract Number: 1374

Flares in Patients with Rheumatoid Arthritis Are Strongly Associated with Worse Clinical Outcomes but Are Difficult to Predict
Abstract Number: 1375

Foot Arthritis : Poor Prognosis Factor in RA
Abstract Number: 1376

Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital
Abstract Number: 1377

The Serum Levels of Semaphorin 4D Are Associated with Disease Activity As Well As Radiographic Progression in Patients with Rheumatoid Arthritis
Abstract Number: 1378

Low HDL Level As a Clinical Marker of Disease Activity in Rheumatoid Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].